Analytical and clinical performance of the new Fujirebio 25-OH vitamin D assay, a comparison with liquid chromatography-tandem mass spectrometry (LC-MS/MS) and three other automated assays by Saleh, Lanja et al.
Clin Chem Lab Med 2016; 54(4): 617–625
*Corresponding author: Dr. Lanja Saleh, Institute of Clinical 
Chemistry, University Hospital of Zurich and University of Zurich, 
Raemistr. 100, 8091 Zurich, Switzerland, Phone: +41-(0)44-255 
2293, Fax: +41-(0)44-255 4590, E-mail: lanja.saleh@usz.ch
Daniel Mueller and Arnold von Eckardstein: Institute for Clinical 
Chemistry, University Hospital of Zurich and University of Zurich, 
Zurich, Switzerland
Lanja Saleh*, Daniel Mueller and Arnold von Eckardstein
Analytical and clinical performance of the new 
Fujirebio 25-OH vitamin D assay, a comparison with 
liquid chromatography-tandem mass spectrometry 
(LC-MS/MS) and three other automated assays
DOI 10.1515/cclm-2015-0427
Received May 6, 2015; accepted August 26, 2015; previously published 
online October 10, 2015
Abstract
Background: We evaluated the analytical and clinical per-
formance of the new Lumipulse® G 25-OH vitamin D assay 
from Fujirebio, and compared it to a liquid chromatogra-
phy-tandem mass spectrometry (LC-MS/MS) method and 
three other commercial automated assays.
Methods: Total 25 hydroxy vitamin D (25(OH)D) levels 
were measured in 100 selected serum samples from our 
routine analysis with Fujirebio 25(OH)D assay. The results 
were compared with those obtained with LC-MS/MS and 
three other automated 25(OH)D assays (Abbott, Beckman, 
and Roche). The accuracy of each assay tested was eval-
uated against a Labquality reference serum panel for 
25(OH)D (Ref!25OHD; University of Ghent).
Results: Intra- and inter-day imprecision of the Fujire-
bio 25(OH)D assay was  < 5%. Fujirebio 25(OH)D assay 
showed the highest correlation among the assays tested 
with the LC-MS/MS method (R = 0.986). The mean relative 
bias obtained was –15.6% (Fujirebio), –12.7% (Beckman), 
–2.1% (Abbott) and 9.7% (Roche) as compared to LC-MS/
MS. Comparison with the Labquality certified reference 
serum panel yielded a mean bias of –11.8% (Fujirebio), 
–14.1% (Beckman), 4.4% (Abbott) and 3.2% (Roche), 
respectively. Compared to LC-MS/MS, the sensitivity of 
different methods in detecting vitamin D insufficiency 
( < 50 nmol/L) varied from 100% for the Fujirebio assay to 
72.7% for Roche, and specificity ranged from 94.4% for 
Roche to 87.6% for Beckman.
Conclusions: The Lumipulse G 25-OH vitamin D assay from 
Fujirebio demonstrated a good correlation with LC-MS/MS 
and some immunoassays. The performance of the assay 
is well-suited for routine 25(OH)D measurement in clini-
cal serum samples. A correction for the observed negative 
bias vs. LC-MS/MS could be considered.
Keywords: 25-hydroxy vitamin D; immunoassays; liquid 
chromatography-tandem mass spectrometry (LC-MS/MS); 
method comparison; vitamin D assays.
Introduction
25-Hydroxy vitamin D (25(OH)D) is the predominant cir-
culating form of vitamin D, and reflects vitamin D status 
[1, 2]. Currently, there is no consensus on the optimum 
threshold concentration of 25(OH)D, but the Institute of 
Medicine (IOM) recommends a threshold of 50 nmol/L for 
bone health [3], whereas the International Osteoporosis 
Foundation (IOF) [4] and the Endocrine Society [5] recom-
mend a threshold of 75 nmol/L for optimal reductions in 
fall or fracture risk. However, the question of whether this 
higher threshold is associated with improvements in other 
health outcomes remains controversial [6].
In addition to the classical role of vitamin D in the 
maintenance of bone health, vitamin D deficiency has 
been associated with increased risks of a number of 
chronic conditions, including cardiovascular disease, dia-
betes, hypertension, some cancers, autoimmune diseases, 
and infectious diseases [3–8]. This growing awareness 
that adequate vitamin D status has potentially beneficial 
effects on a variety of health outcomes has led to a marked 
increase in research in this field. In clinical practice, this 
has been reflected in a substantial rise in requests for 
vitamin D testing. Reliable high-throughput assay systems 
are essential to meet this increasing demand.
Current methods for the measurement of 25(OH)D 
include immunoassays, high performance liquid chroma-
tography (HPLC), competitive protein binding assays and 
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liquid chromatography with tandem mass spectrometry 
(LC-MS/MS). Automated assay systems have been devel-
oped by a number of manufacturers. However, studies 
have shown significant variability, both between assays 
and between laboratories, with these systems [9, 10]. 
Such variability makes the reliability of clinical decisions 
based on absolute cut-off values questionable. Recently, 
the National Institute of Standards and Technology (NIST) 
and the University of Ghent have released standard ref-
erence materials (SRMs) in an attempt to improve the 
performance of currently available 25(OH)D assays. Nev-
ertheless, discrepancies between the results of immuno-
logical assays and reference LC-MS/MS methods persist 
[11–15]. Unacceptable levels of assay bias have been dem-
onstrated in samples from a number of patient groups at 
risk of vitamin D deficiency, including pregnant women, 
haemodialysis patients and patients in intensive care 
units [16, 17].
Recently, Fujirebio introduced the Lumipulse G 25-OH 
vitamin D assay on the LUMIPULSE G 1200 System to the 
European markets. The assay provides a unique assay 
design being the first automated non-competitive sand-
wich assay for measuring 25(OH)D. In this study, we aimed 
to 1) evaluate the analytical performance of the Fujirebio 
25(OH)D assay; 2) evaluate the correlation and agreement 
of the Fujirebio assay with the LC-MS/MS method and 
three other automated total 25(OH)D assays available on 
the market (Abbott, Beckman and Roche; the Beckman 
assay was launched in January 2014); 3) evaluate the 
accuracy of Fujirebio and other selected assays tested 
against the certified reference serum panel for 25(OH)D 
(Ref!25OHD; Labquality, University of Ghent).
The study also investigated the impact of assay vari-
ability on the classification of patients’ vitamin D status 
as insufficiency ( < 50 nmol/L), sufficient (50–75 nmol/L) 
or optimal ( > 75 nmol/L). In addition, the sensitivity, spec-
ificity of each assay in detecting vitamin D insufficiency 
( < 50 nmol/L) were also investigated.
Materials and methods
Study samples
Residual serum samples from 100 patients over 18 years of age submit-
ted to the Institute of clinical chemistry, University Hospital of Zurich 
for routine 25(OH)D measurement were collected after the requested 
tests had been performed. All samples were blinded to patient identi-
fication and information. From each serum sample, five aliquots were 
generated, frozen and stored at –20 °C until re-analysis. At the time of 
analysis, one aliquot of each sample was tested in each assay.
For the accuracy assessment of each assay, we used Labqual-
ity certified reference serum panel “Ref!25OHD”; obtained from Bio-
clin Oy-Labquality, Helsinki. The reference serum panel contains 20 
native serum samples from single donors that have been quantified 
for 25(OH)D by reference measurement procedure (RMP) based on 
the Joint Committee for Traceability in Laboratory Medicine (JCTLM) 
approved isotope dilution mass spectrophotometry (ID-LC-MS/MS) ref-
erence method procedure (RMP) developed at the University of Ghent 
by Prof. Linda Thienpont. Moreover, the accuracy of to the LC-MS/MS 
assay was assessed using standard reference material (SRM) 972a from 
the National Institute of Standards and Technology (NIST).
The study protocol had been approved by the local Zurich Can-
tonal Ethical Committee. No patient informed consent was required.
Measurement of circulating 25(OH)D concentrations
This study assessed the analytical and clinical performance of 
the Fujirebio Lumipulse G 25-OH vitamin D assay applied on the 
LUMIPULSE G 1200 System. The assay is a two-step non-competitive 
sandwich assay based on Chemiluminescent Enzyme Immunoassay 
(CLEIA) that uses a novel steroid compound (X) to extract the 25(OH)
D from VDBP by the effect of a similar steroid compound (X), which 
can extract vitamin D from VDBP. The capture sheep monoclonal 
antibody then specifically recognizes the released 25(OH)D with 
equimolar sensitivity for 25-OH vitamin D2 (25(OH)D2) and 25-OH 
vitamin D3 (25(OH)D3) [18].
Intra- and inter-day imprecision was assessed using 3 levels of 
human serum based quality control materials provided with the kit.
Other commercially automated assays
Serum samples (n = 100) were analysed by means of three compara-
tive commercially available automated assays: from Abbott Diag-
nostics (Abbott Park, IL, USA, Architect 25-OH vitamin D assay, Lot. 
Nr. 00114A000), Beckman Coulter (Beckman Coulter Inc., CA, USA, 
Access 25(OH) vitamin D Total assay, Lot. Nr. 433754) and Roche 
Diagnostics (Mannheim, Germany, total vitamin D assay, Lot Nr. 
17526200).
All 25(OH)D measurements were performed according to the 
manufacturer’s instructions in our ISO 17025 accredited laboratory. 
Characteristics of selected assays according to the package insert of 
each assay are summarized in Table 1. Intra- and inter-day impreci-
sion of each assay (expressed as coefficients of variation) for 20 repli-
cates of 3 levels of quality control materials over 20 subsequent days 
are listed in Table 1.
LC-MS/MS method
The LC-MS/MS method established in our laboratory used commer-
cial standards (ClinCal® 25-OH-vitamin D2/D3; Level 0–3, RECIPE, 
Muenchen, Germany; order number MS7013) that were traceable 
to NIST SRM 972 standards. The calibration standards covered con-
centration ranges of 23.2–180.0 nmol/L for 25(OH)D3 and 17.2–153.0 
nmol/L for 25(OH)D2. The lower limit of quantification (LLOQ) was 
3.75 nmol/L for both 25(OH)D2 and 25(OH)D3, respectively.
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No matrix effect could be observed in the relevant time ranges. 
Details of the LC-MS/MS method are provided in the online Supple-
mentary Data 1.
Statistical analysis
All statistical analyses were performed using Analyse-it Method 
Evaluation Edition (Analyse-it Software, Ltd., Leeds, UK) for Micro-
soft Excel. Concordance between Fujirebio and the other assays with 
in house developed LC-MS/MS method was assessed by means of 
Passing-Bablok regression analysis [19]. Correlation coefficients (R) 
were calculated. Systematic bias and proportional bias were derived 
from the intercept (a) and slope (b), respectively, of the regression 
equations (y = a+bx). Bland-Altman plots [20] were used to assess the 
relative mean difference (bias) and corresponding 95% limit of agree-
ment (±1.96*SD differences).
Agreement between assays in the classification of vitamin D sta-
tus was assessed by Cohn’s kappa coefficient (κ < 0.4 poor agreement; 
κ = 0.4–0.7 fair to good agreement; κ > 0.75 excellent agreement). Dif-
ferences in mean 25(OH)D concentrations between the reference 
method and other methods were analysed by paired t-tests. p-Values 
of  < 0.05 were considered statistically significant. 25(OH)D concen-
tration values are given in molar units (nmol/L); for conversion to 
mass units (ng/mL), divide these by 2.5.
Results
Performance of the in-house LC-MS/MS 
method
Intra-assay and inter-assay imprecision were assessed 
by measuring seven replicates of quality control samples 
over 7 days. Intra-assay CV% was 2.9% and 3.0% for mean 
25(OH)D3 concentrations of 52.5 nmol/L and 206.9 nmol/L, 
respectively. The corresponding inter-assay CV% was 
2.8% and 3.1%. Intra assay CV% was 2.8% and 3.1% for 
mean 25(OH)D2 concentrations of 50.8 and 205.5 nmol/L, 
respectively. The corresponding inter-assay CV% was 3.2 
and 2.9%.
For accuracy testing of our LC-MS/MS method, the 
standard reference material (SRM) 972a from national 
institute of standards and technology (NIST) was used. A 
unit of SRM 972a consists of four vials (level 1–4) of frozen 
serum with different concentration levels of 25(OH)D. 
Levels 1–3 of SRM 972a were prepared from pools of human 
serum with endogenous concentrations of vitamin D 
metabolites. Level 4 consist of a pool of human serum for-
tified with 3-epimer 25-hydroxy vitamin D3 (3-epi-25(OH)
D3). Level 4 was excluded from the accuracy assessment, 
because our LC-MS/MS method does not separate the 
3-epi-25(OH)D3 metabolite. The accuracy obtained for 
total 25(OH)D was 100.1%±3.1% for level 1 (target value Ta
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76.4±2.9 nmol/L) and 96.6%±1.7% for level 2 (target value 
50.3±1.5 nmol/L).
The SRM 972a level three contains significant amounts 
of both native 25(OH)D2 and 25(OH)D3. The accuracy 
obtained for SRM 972a level 3 was 101.5%±0.9% for 25(OH)
D2 (target value of 32.8±0.8 nmol/L), and 103%± 2.1% for 
25(OH)D3 (target value of 49.4±1.1 nmol/L), as shown in 
Supplementary Table 1.
The correlation and the agreement between in-
house LC-MS/MS method and the reference ID-LC-MS/
MS method for the Labquality reference serum panel are 
shown in Figure 1. The two methods showed excellent cor-
relation and agreement with a relative mean bias of –0.4% 
[95% limits of agreement (±1.96 SD); –12.5 to 11.6)] as 
shown in Figure 1B. The estimated bias was clearly under 
the limit of bias (  ≤  5%) as recommended by Stöckl et al. 
[21] and the Vitamin D Standardization Program (VDSP).
Five of the reference serum samples contained signifi-
cant concentrations of 25(OH)D2 ranging from 5.1 nmol/L 
to 55.4 nmol/L corresponding to 9.6% to 48.8% of the total 
25(OH)D. For those 5 samples, our in-house LC-MS/MS 
method agreed with the ID-LC-MS/MS with a mean bias 
of 3.6% [95% limits of agreement (±1.96 SD); –5.8 to 13.0)]. 
The mean accuracy of 25(OH)2 for those five samples was 
107% (95% CI 96.6–118.2).
Precision of the Fujirebio 25-OH vitamin D 
assay
Intra-assay CV% for 20 replicates of quality control 
samples was 3.4%, 1.6%, and 1.3% for mean 25(OH)D 
values 27.4 nmol/L, 79.4 nmol/L and 179.2 nmol/L, respec-
tively. The corresponding inter-assay CV% for 20 subse-
quent days was 4.6%, 2.6%, and 2.4%.
Correlation and agreement of Fujirebio 
25-OH vitamin D assay with 3 other 
automated assays
The results of 100 serum samples measured with the 
Fujirebio 25(OH)D assay were compared with those 
obtained with other automated assays using Passing-
Bablok regression analyses and Bland-Altman agreement 
analysis as demonstrated in Figure 2. According to the 
LC-MS/MS method, only one sample out of 100 serum 
patient samples tested contained quantifiable level of 
25(OH)D2. The concentration of 25(OH)D2 measured was 
5.3 nmol/L, equaling 7.3% of the total 25(OH)D.
The results of 25(OH)D obtained with the  Fujirebio 
assay were well correlated with those obtained for 
both Abbott [slope 0.86 (95% CI 0.77–0.95), intercept 
0.40 nmol/L (95% CI –5.38 to 6.34), R = 0.911], and Beckman 
[slope 1.06 (95% CI 0.93–1.61), intercept –4.66 nmol/L (95% 
CI –10.22 to 3.30), R = 0.880] and less correlated with Roche 
[slope 0.63 (95% CI 0.54–0.72), intercept 12.56 nmol/L (95% 
CI 5.31–19.32), R = 0.829] as shown in Figure 2. Among the 
compared automated assays, excessive proportional bias 
was observed with Roche assay, the mean bias was –25% 
[(95% limits of agreement (±1.96 SD); –74.5 to 24.6)], as 
shown in Figure 2F.
Correlation and agreement of Fujirebio 
25-OH vitamin D assay and 3 other 
automated assays with the in-house 
LC-MS/MS method
In comparison to the LC-MS/MS method, the Fujirebio 
assay demonstrated a strong correlation (R = 0.986) with 
a significant relative mean bias of –15.6% [(95% limits of 
agreement (±1.96 SD); –28.3 to –2.9)] (Figure 3A and E). To 
appraise the noticed negative bias, we compared the three 
other automated assays with the LC-MS/MS method.
As shown in Figure 3, the Fujirebio vitamin D assay 
showed stronger correlations with the in-house LC-MS/
MS as compared to the other three automated immunoas-
says. Both Abbott and Beckmann underestimated 25(OH)
D values with a mean bias of –2.1% [(95% limits of agree-
ment (±1.96 SD); –36.8 to 32.6)] and –12.7% [(95% limits 
of agreement (±1.96 SD); –52.1 to 26.8)], respectively. The 
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Figure 1: Correlation and accuracy testing of in-house LC-MS/MS 
method using Labquality Reference Serum Panel for Total 25(OH)D 
(sum of 25(OH)D2 and 25(OH)D3) (n = 20).
(A) Passing-Bablok regression analyses for comparison between 
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limits of agreement (±1.96 SD).
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(95%CI: 1.17 to 1.56)
Intercept: –16.89
(95%CI: –33.49 to –5.64)
Figure 3: Correlation and agreement of 25(OH) results from 
Fujirebio and three other automated assays versus LC-MS/MS total 
25(OH)D (sum of 25(OH)D2 and 25(OH)D3) using residual patient 
serum samples (n = 100).
Left panel: Passing-Bablok regression analyses for comparisons 
between the LC-MS/MS method (x-axis) and (A) Fujirebio, (B) 
Abbott, (C) Beckman and (D) Roche assay (y-axis). Right panel: 
Bland-Altman bias plots for comparisons between the LC-MS/MS 
and (E) Fujirebio, (F) Abbott, (G) Beckman and (H) Roche assay. The 
blue solid line represents the relative mean difference between 
paired measurements, dashed blue lines indicate upper and lower 
limits of agreement (±1.96 SD).
Roche assay demonstrated a negative bias at concentra-
tions lower than 50 nmol/L, while at concentrations above 
50 nmol/L, the negative bias turned to a positive bias. The 
relative mean bias was 9.7% [(95% limits of agreement 
(±1.96 SD; –41.4 to 60.8)], as shown in Figure 3D and H.
Accuracy assessment for 25(OHD)2 
and 25(OH)D3 testing using Labquality 
reference serum panel (Ref!25OHD)
The correlation and the agreement between Fujirebio and 
the other automated assays and the reference ID-LC-MS/MS 
method for the Labquality reference serum panel are 
shown in Figure 4. The Fujirebio method demonstrated 
high correlation [R = 0.996, slope 0.99 (95% CI 0.93–1.08), 
intercept –6.36 nmol/L (95% CI –12.37 to –2.96)] with 
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a negative relative mean bias of –11.8% [(95% limits of 
agreement (±1.96 SD); –27.9 to 4.2)].
The three other automated assays revealed different 
biases when compared to the reference ID-LC-MS/MS 
method as shown in Figure 4.
The Beckman assay underestimated 25(OH)D values, 
however the Roche assay yielded a positive bias which at 
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Figure 5: Classification of vitamin D status according to 25(OH)D 
measurements performed by the different methods.
Data are presented as the proportion of patients (n = 100) with insuffi-
cient ( < 50 nmol/L), sufficient (50–75 nmol/L) or optimal ( > 75 nmol/L) 
25(OH)D levels, with the number of patients shown within each bar.
least in part due to overestimation at high values. Like-
wise, the Abbott assay revealed a substantial positive bias 
at high 25(OH)D values. For one reference serum sample 
with a target value of 246.5 nmol/L, the measured 25(OH)
D value obtained with Abbott assay exceeded the upper 
measuring limit of the assay ( > 400 nmol/L) giving a per-
centage error of  > 61.5%.
Five of the reference serum samples contained sig-
nificant concentrations of 25(OH)D2 ranging from 5.1 to 
55.4 nmol/L and making 9.6 to 48.8% of the total 25(OH)D.
For those five samples, all automated assays tested 
demonstrated a negative mean bias as compared to the 
reference method (ID-LC-MS/MS). The relative mean bias 
for each automated method was –11.1% [(95% limits of 
agreement (±1.96 SD); –14.5 to –7.8)], –11.2% [(95% limits 
of agreement (± 1.96 SD); –37.2 to 14.8)], –15.8% (95% limits 
of agreement (±1.96 SD); –27.7 to –4.0)], and –3.2% [(95% 
limits of agreement (±1.96 SD); –20.2 to 13.7)] for Fujirebio, 
Abbott, Beckman and Roche, respectively. The mean bias 
of both Fujirebio and Beckman differed significantly from 
the results obtained with ID-LC-MS/MS method.
Impact of assay performance on clinical 
assessment of vitamin D status
The impact of variability in 25(OH)D results from different 
automated assays on the classification of patients’ vitamin 
D status as insufficient ( < 50 nmol/L), sufficient (50–75 
nmol/L) or optimal ( > 75 nmol/L) are shown in Figure 5.
According to the LC-MS/MS results, 11/100 patients 
(11%) were classified having vitamin D insufficiency 
( < 50  mol/L), the proportion with Fujirebio method was 
19% [sensitivity: 100% (95% CI: 71.3%–100%), specificity 
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Figure 4: Correlation and accuracy testing of each assay using 
Labquality reference serum panel (n = 20).
Left panel: Passing-Bablok regression analyses for comparisons 
between reference total 25(OH)D (sum 25(OH) D2 and D3) values meas-
ured with ID-LC-MS/MS method (x-axis) and (A) Fujirebio, (B) Abbott, 
(C) Beckman and (D) Roche assay (y-axis). Right panel: Bland-Altman 
bias plots for comparisons between the reference ID-LC-MS/MS 
(x-axis) and (E) Fujirebio, (F) Abbott, (G) Beckman and (H) Roche assay 
(y-axis). The blue solid line represents the relative mean difference 
between paired measurements, dashed blue lines indicate upper and 
lower limits of agreement (±1.96 SD). One and two reference samples 
were excluded for the Abbott and Roche assay, respectively, because 
the values obtained exceeded the linear measuring range of the assay.
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91% (95% CI: 83.1%–96%)]. The corresponding propor-
tions with the three other automated methods was 12% 
with the Abbott assay [sensitivity: 90.9% (95% CI: 58.7%–
98.5%), specificity 97.8% (95% CI: 92.1%–99.7%)], 21% 
with the Beckman method [sensitivity: 90.9% (95% CI: 
58.7%–98.5%), specificity 87.6% (95% CI: 79%–93.7%)] 
and 13% with the Roche method [sensitivity: 72.7% (95% 
CI: 39.1%–93.7%), specificity 94.4% (95% CI: 87.4%–
98.1%)], as shown in Figure 5.
Considering 50 nmol/L threshold for insufficiency, 
the Abbott assay results demonstrated a good agreement 
with the LC-MS/MS method (κ = 0.85), whereas the Fujire-
bio and the two other automated methods showed mod-
erate agreement; Fujirebio (κ = 0.66), Roche κ = 0.62) and 
Beckman (κ = 0.56).
Discussion
This study was conducted to evaluate the analytical and 
clinical performance of Fujirebio’s Lumipulse G 25-OH 
vitamin D assay and to compare it to an in-house LC-MS/
MS method and three other automated assays. The Fujire-
bio assay showed an acceptable imprecision over the entire 
measuring range. Among the immunoassays tested, the 
Fujirebio assay demonstrated the highest correlation with 
the LC-MS/MS method, however with a consistent negative 
mean bias. Similar performance of the assay was observed 
in the assay accuracy testing using the Labquality reference 
serum panel vs. the reference ID-LC-MS/MS method. For the 
observed negative bias of the Fujirebio 25(OH)D assay vs. 
both LC-MS/MS methods, a correction could be considered.
In general, the Fujirebio assay demonstrated an 
acceptable correlation with other automated assays tested 
in this study except for the Roche assay.
This study adds to a growing literature [9–17, 22–28] 
that has shown marked variations in the performance of 
commercial assays for 25(OH)D. Compared to LC-MS/MS, 
each of Fujirebio, Beckman and Abbott assays underes-
timated 25(OH)D values in the serum samples measured, 
whereas the Roche method resulted in overestimation of 
25(OH)D particularly at values above 50 nmol/L. Overes-
timation of 25(OH)D values with both Abbott Architect 
and Roche Elecsys in the upper part of the measuring 
range has been reported previously which may in part 
due to calibration problem of these two assays at high 
25(OH)D concentrations [13, 15, 23]. In the accuracy per-
formance testing using Labquality reference serum panel, 
both Roche and Abbott displayed a similar bias at higher 
25(OH)D concentrations as with study serum samples.
These differences in assay performance translated 
into marked discrepancies in the classification of patients’ 
vitamin D status. The proportion of patients who were 
classified as being vitamin D insufficient was consider-
ably overestimated with automated assays as compared 
to the LC-MS/MS method. This has clear implications for 
clinical decision making, as it can lead to over-treatment. 
For example, with the Beckman assay, almost one in two 
patients was wrongly classified as being vitamin D insuf-
ficient, compared to the results obtained with the LC-MS/
MS method. Such discrepancies have been documented 
previously for currently available 25(OH)D assays [11, 15] 
and it is clear that results may not be directly comparable 
if assays are performed in different laboratories using dif-
ferent methods.
Although LC-MS/MS is widely accepted as the ‘gold 
standard’ for the measurement of 25(OH)D [24], and is the 
only method capable of measuring all known vitamin D 
metabolites, automated systems such as those evaluated 
in this study have an important place in clinical labora-
tory practice, particularly in view of the current growth 
in demand for vitamin D assays. They offer a number of 
advantages over LC-MS/MS assays, particularly in terms 
of turn-around and convenience. Furthermore, LC-MS/
MS assays require specialized equipment and expertise. 
However, the development of automated assays for 25(OH) 
has proved to be problematic [12]. Vitamin D is difficult 
to measure, for a number of reasons. It is a small hydro-
phobic molecule, and therefore subject to matrix effects 
resulting from interference by lipids: this problem is not 
encountered with chromatographic or competitive protein 
binding assays. In addition, it is tightly bound to vitamin D 
binding protein (VDBP), which can compete with captur-
ing antibodies used in immunoassays, or with other com-
petitive binding proteins; inaccuracy in some of Abbott’s 
Architect assay, has been shown to be largely dependent 
on VDBP concentrations [16, 17, 22].
A further problem is the difficult extraction of the 
vitamin from VDBP by automated assays. Fujirebio uses 
novel steroid compound (X) to extract the 25(OH)D from 
VDBP by the effect of a similar steroid compound (X), 
which can extract vitamin D from VDBP. Whether this 
novel extraction procedure leads to a better release of 
VDBP and more accurate 25(OH)D measurement remains 
to be proven. Further studies are needed to evaluate the 
performance of Fujirebio assay in patient populations 
with various amounts of VDBP like pregnant women and 
hemodialysis patients.
Furthermore, antibodies used in the different assays 
have varying cross-reactivities with other vitamin D 
metabolites, and this presents another source of variation 
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between assays. As shown in Table 1, some automated 
immunoassays and protein binding assay exhibit non-
equimolar detection of 25(OH)D3 and the less active 
metabolite 25(OH)D2; however, the concentration of 
25(OH)D2 relative to total vitamin D concentrations in 
our routine specimens is minor. It is noteworthy that 
with our LC-MS/MS method, only one sample out of 100 
serum samples tested in this study contained quantifi-
able amounts of 25(OH)D2. The concentration of 25(OH)
D2 measured was 5.29 nmol/L, equaling 7.25% of the total 
25(OH)D. In the accuracy testing using Labqualtiy refer-
ence serum samples that contained significant amounts 
of 25(OH)D2, all automated assays tested underestimated 
total 25(OH)D values as compared with the reference ID-
LC-MS/MS values. The mean differences ranged from 
–3.24% (Roche) to –15.83% (Beckman). In Switzerland 
and several European countries, vitamin D2 is irrelevant 
because vitamin D2 supplements are not used, in contrast 
to United States, where vitamin D2 supplementation is 
typically used. Further studies are needed to assess the 
performance of Fujirebio assay in samples containing 
varies amounts of endogenous 25(OH)D2.
The cross-reactivity toward the recently identified 
3-epi 25(OH)D3, as reported by the assay manufacturers, 
varies between 2.7% with the Abbott method to 91% with 
the Roche method. However, it was shown that Roche assay 
recognizes 3-epimer metabolite when added by spiking, but 
not when it is native [25]. The impact of 3-epi-25(OH)D3 has 
been shown to be significant in infants, where it accounts 
for 15%–41% of the total 25(OH)D, compared with 2.5%–17% 
in adults [26]. Currently, there are no recommendations for 
routine measurement and reporting the 3-epimer metabo-
lite, as the physiological importance of the C3-epimerization 
pathway is not fully understood. It is noteworthy that sepa-
ration of the 3-epimer of 25(OH) vitamin D3 is not possible 
with our LC-MS/MS method as the 3-epimer has an identical 
mass/charge ratio to 25(OH)D3, and was thus falsely meas-
ured as this metabolite. However, this limitation is unlikely 
to explain the significant negative biases observed against 
our LC-MS/MS because both Beckman and Fujirebio assays 
demonstrated similar negative bias in the assay accuracy 
testing as compared to target values measured with the ref-
erence ID-LC/MS/MS method (sum of 25(OH)2 and 25(OH)
D3 excluding the 3-epimer metabolite values).
The recent introduction of SRMs such as SRM 972a, 
which was used to standardize the calibrators of the 
LC-MS/MS assay used in this study, has reduced variabil-
ity between assays, but the performance of many assays 
remains suboptimal particularly in patients containing 
different amounts of VDBP like pregnant women and 
hemodialysis patients [27].
For the current study, correlation coefficients 
obtained between automated assays and LC-MS/MS 
methods are higher for the Labquality samples (20 serum 
samples from healthy donors) than those for our study 
samples from routine clinical practice (n = 100). Interest-
ingly, no difference was observed when comparing the 
Fujirebio results with the LC-MS/MS method for Labqual-
ity samples (R = 0.996) vs. study samples (R = 0.986), which 
may indicate that Fujirebio assay is less sensitive to serum 
matrix effects than other automated assays tested. Further 
studies are needed to confirm this observation.
In conclusion, measuring 25(OH)D is still challeng-
ing for clinical laboratories. Generally, the new Fujirebio 
25-OH vitamin D assay correlates well with most auto-
mated assays tested and with the LC-MS/MS method. The 
performance of the assay is well-suited for routine 25(OH)
D measurement in clinical serum samples.
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